Cytosorbents Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cytosorbents Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $6.08M | Mar 7, 2019 |
| FY2018 | Sep 30, 2018 | $5.74M | Mar 7, 2019 |
| FY2018 | Jun 30, 2018 | $5.76M | Mar 7, 2019 |
| FY2018 | Mar 31, 2018 | $4.92M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $4.65M | Mar 7, 2019 |
| FY2018 | Sep 30, 2017 | $3.82M | Mar 7, 2019 |
| FY2018 | Jun 30, 2017 | $3.57M | Mar 7, 2019 |
| FY2018 | Mar 31, 2017 | $3.11M | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $3.08M | Mar 7, 2019 |
| FY2018 | Sep 30, 2016 | $2.41M | Mar 7, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.65M | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $3.82M | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $3.57M | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $3.11M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $3.08M | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $2.41M | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $2.22M | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $1.81M | Mar 8, 2018 |
| FY2017 | Dec 31, 2015 | $1.76M | Mar 8, 2018 |
| FY2017 | Sep 30, 2015 | $1.34M | Mar 8, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.49M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $24.89M | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | $5.31M | Mar 15, 2024 |
| FY2023 | Sep 30, 2023 | $5.61M | Mar 15, 2024 |
| FY2023 | Jun 30, 2023 | $6.02M | Mar 15, 2024 |
| FY2023 | Mar 31, 2023 | $5.46M | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $5.76M | Mar 15, 2024 |
| FY2023 | Sep 30, 2022 | $3.62M | Mar 15, 2024 |
| FY2023 | Jun 30, 2022 | $4.94M | Mar 15, 2024 |
| FY2023 | Mar 31, 2022 | $6.41M | Mar 15, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.20M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($20.72M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($29.25M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($32.81M) | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | ($24.56M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($7.84M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | ($19.27M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($17.21M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($8.46M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | ($11.76M) | Mar 7, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.75M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($16.45M) | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | ($9.41M) | Mar 15, 2024 |
| FY2023 | Sep 30, 2023 | ($7.35M) | Mar 15, 2024 |
| FY2023 | Jun 30, 2023 | ($6.56M) | Mar 15, 2024 |
| FY2023 | Mar 31, 2023 | ($7.89M) | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | ($6.36M) | Mar 15, 2024 |
| FY2023 | Sep 30, 2022 | ($9.02M) | Mar 15, 2024 |
| FY2023 | Jun 30, 2022 | ($8.36M) | Mar 15, 2024 |
| FY2023 | Mar 31, 2022 | ($7.79M) | Mar 15, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $15.73M | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $15.12M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $16.38M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $8.81M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $12.09M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $7.72M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $3.22M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $4.07M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $3.87M | Mar 8, 2018 |
| FY2016 | Dec 31, 2014 | $2.43M | Mar 3, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.65M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $33.73M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $38.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $34.29M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $35.75M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $28.46M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $22.01M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $20.87M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $14.91M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $11.81M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.38M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.43M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($21.66M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($28.23M) | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | ($14.01M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($5.61M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | ($16.76M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($10.84M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($6.46M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | ($6.73M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $284.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $538.1K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.09M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $3.64M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $708.4K | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $698.2K | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $672.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $990.7K | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $140.7K | Mar 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $47.37M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $47.80M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $53.43M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $47.07M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $52.96M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $47.58M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $52.44M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $57.46M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $63.23M | Mar 15, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.28M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $36.27M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $34.66M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $36.00M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $27.44M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $29.48M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $28.76M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $27.98M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $27.52M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $27.86M | Mar 15, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.90M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $11.11M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $13.14M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $17.43M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $19.63M | Mar 31, 2025 |
| FY2025 | Dec 31, 2023 | $23.48M | Mar 30, 2026 |
| FY2024 | Sep 30, 2023 | $18.81M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $24.46M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $29.94M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $35.37M | Mar 31, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($312.21M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($304.01M) | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | ($296.44M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | ($293.67M) | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | ($289.38M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($283.29M) | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | ($277.14M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | ($267.97M) | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | ($261.36M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($254.00M) | Mar 15, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.25M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.28M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $14.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $22.14M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $52.14M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $71.42M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $12.23M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $22.37M | Mar 5, 2020 |
| FY2019 | Dec 31, 2017 | $17.32M | Mar 5, 2020 |
| FY2019 | Dec 31, 2016 | $5.25M | Mar 5, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.04M | Mar 15, 2024 |
| FY2020 | Dec 31, 2020 | $0 | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $15.05M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $9.94M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $9.99M | Mar 7, 2019 |
| FY2016 | Dec 31, 2016 | $4.91M | Mar 3, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Mar 15, 2024 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Mar 15, 2024 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.80M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 54.83M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 54.24M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 43.64M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 43.64M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 43.22M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 32.62M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 31.77M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 28.97M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 25.48M | Mar 8, 2018 |